top of page

A reservoir of stem-like CD8 T cells in the tumor-draining lymph node maintains the ongoing anti-tumor immune response

Connolly et al. (BioRxiv) DOI: 10.1101/2021.01.27.428467



  • Stem-like CD8 T cells

  • Cold ‘non-inflammed’ tumors

  • Tumor draining lymph node


Main Findings

​Stem-like CD8+ T cells (TCF1+, PD1+, SLAMF6+; TSL) reside in tumor-draining lymph nodes that can migrate to tumors where they undergo differentiation to terminal states. This niche serves as a reservoir away from repeated antigen exposure, from which intratumoral T cells that become exhausted can be replenished. Successful ongoing antitumor responses are thus dependent on TSL, and tumor-draining lymph nodes may house an untapped pool of T cells reactivatable against non-inflamed, “cold” tumors.


  • PHATE embedding was done on very few cells (<2000), potential for overfitting of clusters → human samples with previous clustering had nice signatures

  • Only dLN were sampled. What about tertiary lymphoid structures (TSLs)?

  • Only a single neoantigen, but tumors elicit polyclonal responses.


  • Untapped source of antigen-specific, non-exhausted CD8+ T cells in the lymph nodes of patients could provide effector cells to non-responsive ‘cold’ tumors.

  • As a majority of patients do not respond to immunotherapy alone, these findings suggest a new niche of cells capable of providing renewed anti-tumor effectors that could help address this problem.

  • KP-NINJA model of autochthonous inducible neoantigen expression proves useful.


Reviewed by Matthew Lin as part of the cross-institutional journal club of the Immunology Institute of the Icahn School of Medicine, Mount Sinai and the Kennedy Institute of Rheumatology, University of Oxford. Follow him on Twitter.

bottom of page